SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's has become the latest focal point for retail investors, experiencing extreme volatility and heavy volume driven by speculation of a potential short squeeze. Community members are actively sharing their positions and coordinating efforts to hold shares, drawing parallels to past meme stock rallies while reacting to multiple trading halts.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid significant investor volatility, fueled by persistent community concerns over share dilution and the stock's decoupling from Bitcoins price action. Investors are actively debating whether the current pullback to long-term support levels represents a generational buying opportunity or the beginning of a deeper structural decline.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense debate as it hits new 52-week lows, with bulls highlighting the Zeta Global partnership and strong defense contracts as indicators of long-term value, while bears point to persistent short-term downward momentum and concerns over high valuation multiples. Investors are actively monitoring key support levels near $100-$106, debating whether this is a structural distribution phase or a deep-value buying opportunity for long-term holders.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing significant volatility as market participants debate whether recent price declines represent a fundamental shift or a temporary correction linked to broader economic uncertainty. Community discussions are heavily divided between long-term investors citing industrial shortages and physical accumulation as a floor, and traders expressing frustration over the asset's inability to sustain gains despite geopolitical headlines.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing extreme volatility as investors weigh a strong revenue beat and multi-billion dollar partnerships against concerns regarding shrinking margins and upcoming insider share lockup expirations. The community remains deeply divided, with some betting on a rapid recovery fueled by AI hardware demand while others anticipate a sharp correction as they scrutinize the stock's valuation and potential selling pressure.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following the announcement of a strategic agreement with Fit Energy to supply up to 380MW of clean, on-site power for AI data centers, with an immediate deposit for the first 30MW. While the community is debating the credibility of the partner and the structure of the deal, many bulls are focused on the validation of FCEL's utility-scale tech within the high-demand data center power sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is facing intense selling pressure as investors rotate out of gold, driven by concerns that persistent inflation and a strong dollar will force the Federal Reserve to maintain higher interest rates. The community is sharply divided, with bulls viewing the drop as a structural buying opportunity near key support levels, while bears are aggressively shorting the ETF, anticipating further downside as gold's safe-haven appeal wanes.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is surging as investors react to high-profile executive orders prioritizing quantum technology, with community sentiment boosted by the CEO's direct participation in White House policy discussions. Traders are actively debating whether this momentum will trigger a sustained breakout, focusing heavily on potential institutional index inclusion and upcoming technical product updates.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is experiencing a significant surge following an agreement with Renew Home and Tesla to develop a large-scale virtual power plant, which the community sees as a major catalyst for grid infrastructure and AI-driven energy demand. Investors are actively discussing the stock's high short interest as a potential tailwind for further upward momentum and price discovery.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci Corp is gaining significant attention due to positive clinical updates on its antibody candidate for hair loss and a fresh injection of capital from major healthcare investors. The community is actively debating the potential for a short squeeze given the stock's high short interest and the strategic participation of industry heavyweights like Eli Lilly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ITRM    If I compare my impression from March with the one I have now, the difference is that in March I saw it as just another pharmaceutical liquidation (a failed asset and lack of liquidity). 
Today, I see an extraordinarily orderly liquidation centered around an asset that continues to show signs of commercial life and strategic relevance months after the insolvency began. 
This doesn’t guarantee a favorable outcome for the shareholders, but it does make the case much less typical than it seemed when Teneo first stepped in. 
We’ll see if the process is being handled cleanly and whether the creditors aren’t inflating their claims. We have a guardian on our side: a judge and a company (Teneo) with a reputation to protect.

Nanda Lee

yoyo123456564

Wayne

Stephen

Jordan

Investor Man

Mr.Yoda

Swedishviking1

StockTwits Web

Iterum Therapeutics Plc

    If I compare my impression from March with the one I have now, the difference is that in March I saw it as just another pharmaceutical liquidation (a failed asset and lack of liquidity). 
Today, I see an extraordinarily orderly liquidation centered around an asset that continues to show signs of commercial life and strategic relevance months after the insolvency began. 
This doesn’t guarantee a favorable outcome for the shareholders, but it does make the case much less typical than it seemed when Teneo first stepped in. 
We’ll see if the process is being handled cleanly and whether the creditors aren’t inflating their claims. We have a guardian on our side: a judge and a company (Teneo) with a reputation to protect.

Juan Carlos

StockTwits for iOS

RonBurgundysBroker

@XJCX You can take it one large step further.  Iterum never intended to do anything more than a micro test of adoption.  Their dual path was always aimed at a strategic transaction and the focus of their 9 person team and only key hire (Coyne) was to lock in all three PBM and Medicare D coverage.

In hindsight, we were given the script a year in advance when they started planning full steam ahead for liquidation, but missed the forest for the trees.

The scary part (in a good way), Iterum has infinitely more leverage today than Spero did when GSK gave them $640M in cash and incentives.  SPRO has bloated overhead, single drug without approval at the time, and the inability to cover notes due.  

Imagine being Teneo armed with Orlynvah: fully clean, minimal debt, ultra low Operating burn in an ever improving AMR macro back drop and infinite optionality

https://www.fiercepharma.com/pharma/breaking-down-dual-track-strategy-behind-iterums-launch-first-new-uncomplicated-uti-drug

ALAS

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs) in the U.S., Dublin-based Iterum Therapeutics has made it to market fi | With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections in the U.S., Dublin-based Iterum Therapeutics has made it to market first, edging out generics juggernaut Alembic Pharmaceuticals and British Big Pharma GSK.

Fierce Pharma

Behind Iterum's 'dual-track' strategy to launch nation's first new uncomplicated UTI drug in 25 years

 You can take it one large step further.  Iterum never intended to do anything more than a micro test of adoption.  Their dual path was always aimed at a strategic transaction and the focus of their 9 person team and only key hire (Coyne) was to lock in all three PBM and Medicare D coverage.

In hindsight, we were given the script a year in advance when they started planning full steam ahead for liquidation, but missed the forest for the trees.

The scary part (in a good way), Iterum has infinitely more leverage today than Spero did when GSK gave them $640M in cash and incentives.  SPRO has bloated overhead, single drug without approval at the time, and the inability to cover notes due.  

Imagine being Teneo armed with Orlynvah: fully clean, minimal debt, ultra low Operating burn in an ever improving AMR macro back drop and infinite optionality



@DollerADay  The idea that Iterum was trying to &quot;unblock&quot; or &quot;clear up&quot; the coverage before a sale seems very spot on to me, and that would explain many of the actions we previously had no explanation for.

WindowShopper

  The idea that Iterum was trying to "unblock" or "clear up" the coverage before a sale seems very spot on to me, and that would explain many of the actions we previously had no explanation for.

@XJCX when he announced liquidation I was surprised- but then instantly thinking: he’s doing this for a reason. Why? He put millions into this company as seed money. He’d lose that, ie his shares go to zero, and no CoC bonus because company wasn’t being “sold.”- but… dollar did some digging- his options vest upon liquidation. As a FORMER CEO, now he’s free to buy shares at $.03/share. as long as he doesn’t buy more than 4.99%, no 13D required. Explains why he dodged my direct questions of “buy some shares Corey! It’s embarrassing how few shares you and rest of leadership team have”… why buy any shares at $.50/share if you know you’re headed to liquidation? Plenty of time to buy at $.03/share once liquidation announced; or… to have your unvested options vest, and get those shares for free….

 when he announced liquidation I was surprised- but then instantly thinking: he’s doing this for a reason. Why? He put millions into this company as seed money. He’d lose that, ie his shares go to zero, and no CoC bonus because company wasn’t being “sold.”- but… dollar did some digging- his options vest upon liquidation. As a FORMER CEO, now he’s free to buy shares at $.03/share. as long as he doesn’t buy more than 4.99%, no 13D required. Explains why he dodged my direct questions of “buy some shares Corey! It’s embarrassing how few shares you and rest of leadership team have”… why buy any shares at $.50/share if you know you’re headed to liquidation? Plenty of time to buy at $.03/share once liquidation announced; or… to have your unvested options vest, and get those shares for free….

@XJCX 
FishFuck is a criminal who will no doubt rot in hell someday

 
FishFuck is a criminal who will no doubt rot in hell someday